WO2000021506A3 - Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy - Google Patents
Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy Download PDFInfo
- Publication number
- WO2000021506A3 WO2000021506A3 PCT/CA1999/000949 CA9900949W WO0021506A3 WO 2000021506 A3 WO2000021506 A3 WO 2000021506A3 CA 9900949 W CA9900949 W CA 9900949W WO 0021506 A3 WO0021506 A3 WO 0021506A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glutathione
- arsenic
- antimony
- modulators
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60746/99A AU6074699A (en) | 1998-10-13 | 1999-10-12 | Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,250,631 | 1998-10-13 | ||
CA2250631 | 1998-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000021506A2 WO2000021506A2 (en) | 2000-04-20 |
WO2000021506A3 true WO2000021506A3 (en) | 2000-07-20 |
Family
ID=4162919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/000949 WO2000021506A2 (en) | 1998-10-13 | 1999-10-12 | Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6074699A (en) |
WO (1) | WO2000021506A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002226382A (en) * | 2001-01-31 | 2002-08-14 | Gifu International Institute Of Biotechnology | Therapeutic agent for cancer |
WO2002096412A1 (en) | 2001-05-31 | 2002-12-05 | The Cleveland Clinic Foundation | Ptpase inhibitors and method of using same |
EP1572070A4 (en) | 2001-09-07 | 2009-11-04 | Cleveland Clinic Foundation | Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
US20100173864A1 (en) | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
ES2629682T3 (en) | 2004-03-29 | 2017-08-14 | University Of South Florida | Effective treatment of tumors and cancer with triciribin phosphate |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0412211A1 (en) * | 1982-09-17 | 1991-02-13 | Therapeutical Systems Corporation | Cancer therapy system |
WO1996022791A1 (en) * | 1995-01-13 | 1996-08-01 | Octamer, Inc. | Novel synergistic compositions useful as anti-tumor or anti-retroviral agents |
WO1998008566A1 (en) * | 1996-08-30 | 1998-03-05 | Duke University | Manipulations of nitrosative and oxidatives stress in the treatment of disease |
-
1999
- 1999-10-12 AU AU60746/99A patent/AU6074699A/en not_active Abandoned
- 1999-10-12 WO PCT/CA1999/000949 patent/WO2000021506A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0412211A1 (en) * | 1982-09-17 | 1991-02-13 | Therapeutical Systems Corporation | Cancer therapy system |
WO1996022791A1 (en) * | 1995-01-13 | 1996-08-01 | Octamer, Inc. | Novel synergistic compositions useful as anti-tumor or anti-retroviral agents |
WO1998008566A1 (en) * | 1996-08-30 | 1998-03-05 | Duke University | Manipulations of nitrosative and oxidatives stress in the treatment of disease |
Non-Patent Citations (10)
Also Published As
Publication number | Publication date |
---|---|
AU6074699A (en) | 2000-05-01 |
WO2000021506A2 (en) | 2000-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7031500A (en) | Therapeutic quinazoline compounds | |
NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
AU1107500A (en) | Tooth path treatment plan | |
AP9801392A0 (en) | Concentrated antibody preparation. | |
WO1999043355A3 (en) | Formulations containing oxaliplatin | |
AU2002351753A1 (en) | Combined use of a glp-1 compound and a modulator of diabetic late complications | |
WO2003039632A3 (en) | A medicament container, a medicament dispensing kit for administering medication and a method for packaging the same | |
AU2002236765A1 (en) | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent | |
AU1392900A (en) | 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses | |
AU6754496A (en) | Medicine comprising hgf gene | |
WO1996003151A3 (en) | Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy | |
BR9610386A (en) | Use of a compound capable of antagonizing, at least partially, the oncogenic activity of the mdm2 protein, use of an scfv, directed against the 1-134 domain of the mdm2 protein, use of a nucleic acid encoded for a compound capable of antagonizing the oncogenic activity mdm2 protein, viral vector and pharmaceutical composition | |
AU4155897A (en) | Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles | |
AU2001247968A1 (en) | Use of asiatic acid or asiaticoside for treatment of cancer | |
IL131229A (en) | Compounds having enzymatic conversion inhibition for therapeutic intervention in preventing diabetic complications, pharmaceutical preparations and uses thereof | |
WO2000021506A3 (en) | Pharmaceutical composition of glutathione modulators with antimony and/or arsenic for cancer therapy | |
CA2280773A1 (en) | Methods for the administration of amifostine | |
UA32457C2 (en) | Drug (variants) and methods for exposure to drug | |
AU5892399A (en) | 1, 2, 4-triazole-3-thione compounds | |
BR9814419A (en) | "combination of benzocycloheptapyridine compounds and antineoplastic drugs for the treatment of proliferative diseases" | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
MXPA02005045A (en) | Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer. | |
AU8851298A (en) | L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof | |
AU1469097A (en) | Pharmaceutical compounds | |
AU2003221096A1 (en) | Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09807393 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |